Anyone looking to upgrade their breakfast setup may be interested in Dunelm's "work of art" retro-style gloss toaster ...

Gym Plus is spotlighting its Strength Machines collection, a series of plate-loaded training products developed to ...

Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at ...

ARVO presenters conducted a retrospective study to assess the visual and anatomical outcomes of patients receiving complement inhibitors for geographic atrophy. In a real-world cohort of patients with ...

(Getty) Recent developments in complement biology and targeted therapies represent important advancements in addressing some of the unresolved challenges in AAV. Despite major therapeutic advances, ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...

The FDA has approved Omeros' Yartemlea as the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. It is the first FDA nod for the 31-year-old Seattle biotech.

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...

Among the most significant genetic risk factors for age-related macular degeneration is the Y402H variant of complement factor H, which, along with its splice isoform FHL-1, impairs binding to the ...

The complement system protects against infection, positively responds to tissue damage, clears cell debris, directs and modulates the adaptive immune system, and functions in neuronal development, ...